Table 1 Comparisons of baseline characteristics of patients with T2D with and without MAFLD
Non-MAFLD N = 1723 | MAFLD N = 824 | P-value | |
|---|---|---|---|
Age, years | 60.24 ± 10.80 | 54.70 ± 11.43 | < 0.001 |
Gender, %(N) | |||
Female | 57% (983) | 52.66% (434) | 0.022 |
Male | 43% (741) | 47.33% (390) | |
Duration of DM, years | 10.87 ± 8.60 | 9.55 ± 7.35 | < 0.001 |
SBP, mmHg | 133.37 ± 36.24 | 132.94 ± 76.45 | 0.877 |
DBP, mmHg | 78.22 ± 9.90 | 79.49 ± 7.52 | 0.001 |
BMI, kg/m2 | 28.60 ± 5.10 | 30.65 ± 5.10 | < 0.001 |
Waist/hip | 0.94 ± 0.22 | 0.94 ± 0.06 | 0.456 |
eGFR, mL/min/1.73 m2 | 79.11 ± 32.15 | 90.85 ± 36.34 | < 0.001 |
Microalbuminuria | 19.5% (230) | 17.1% (92) | 0.126 |
HOMA-IR | 3.37 ± 3.03 | 4.74 ± 3.09 | < 0.001 |
HDL, mg/dl | 45.14 ± 11.90 | 43.88 ± 11.40 | 0.010 |
Non-HDL, mg/dl | 135.63 ± 41.57 | 143.52 ± 43.40 | 0.003 |
LDL, mg/dl | 95.43 ± 33.69 | 103.04 ± 34.35 | < 0.001 |
TG, mg/dl | 165.93 ± 93.22 | 189.03 ± 112.52 | < 0.001 |
HbA1C, % | 8.32 ± 1.752 | 7.40 ± 1.53 | 0.031 |
FBS, mg/dl | 160.72 ± 57.31 | 152.82 ± 51.83 | 0.001 |
AST, U/L | 19.69 ± 10.95 | 29.97 ± 18.31 | < 0.001 |
ALT, U/L | 22.36 ± 11.10 | 42.45 ± 28.07 | < 0.001 |
ALKP, U/L | 150.29 ± 74.89 | 167.60 ± 90.80 | < 0.001 |
GGT, U/L | 21 (16,33) | 30.7 (20,40.25) | 0.013 |
AIP | 0.52 ± 0.25 | 0.59 ± 0.26 | < 0.001 |
Anti-lipid therapy | |||
+ | 78% (1343) | 65.8% (542) | < 0.001 |
− | 22% (380) | 34.2% (282) | |